GDOC - ETF AI Analysis
Top Page
Goldman Sachs Future Health Care Equity ETF (GDOC)
Rating:70Neutral
Price Target:―
Positive Factors
Established Healthcare Leaders in Top Holdings
Several major pharmaceutical and medical technology companies sit among the largest positions, providing exposure to well-known, financially solid businesses.
Focused Healthcare Exposure
The fund is heavily concentrated in the health care sector, which can benefit investors who want targeted exposure to long-term trends in medicine and biotechnology.
Global Healthcare Reach
While most holdings are U.S.-based, the ETF also includes companies from Switzerland, Japan, and France, adding some international diversification within healthcare.
Negative Factors
High Expense Ratio
The fund’s relatively high annual fee means more of the investment return is used to cover costs instead of staying in investors’ pockets.
Recent Weak Performance
The ETF has shown negative performance over the year to date and over the last three months, indicating recent struggles in its strategy or holdings.
Concentration in a Single Sector and a Few Stocks
With most assets in healthcare and a meaningful share in a small number of companies, investors face higher risk if this sector or these specific stocks perform poorly.
GDOC vs. SPDR S&P 500 ETF (SPY)
AUM20.40M
RegionGlobal
Expense Ratio0.75%
Beta0.68
IssuerGoldman Sachs
Inception DateNov 09, 2021
Dividend Yield0.35%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume390
30 Day Avg. Volume1,865
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
41.91Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering42
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GDOC Summary
The Goldman Sachs Future Health Care Equity ETF (GDOC) focuses on the future of health care, especially health care technology like digital health tools, telemedicine, biotech, and advanced medical devices. It does not track a traditional index, but instead holds a selected mix of health-focused companies, mainly in the U.S. Well-known holdings include Eli Lilly and Johnson & Johnson. Someone might invest in GDOC to seek long-term growth from innovation in medicine and health technology. However, it is concentrated in one sector, so its price can rise and fall sharply with changes in the health care industry.
How much will it cost me?The Goldman Sachs Future Health Care Equity ETF (GDOC) has an expense ratio of 0.75%, meaning you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care technology companies that require more research and expertise to select.
What would affect this ETF?The Goldman Sachs Future Health Care Equity ETF (GDOC) could benefit from increasing demand for health care technology, driven by advancements in telemedicine, biotech, and medical devices, as well as global aging populations requiring innovative solutions. However, it may face challenges from regulatory changes in the health care sector, fluctuating interest rates affecting growth-focused companies, and potential competition or setbacks in technological adoption. Its global exposure and focus on leading companies like Eli Lilly and Boston Scientific provide both opportunities and risks tied to the broader health care industry trends.
GDOC Top 10 Holdings
GDOC is firmly hitched to the future of health care, with nearly all its firepower in global drugmakers and medical technology names. Eli Lilly is a heavyweight in the portfolio but has been losing steam this year, while steadier giants like Johnson & Johnson and Merck help keep the ride smoother. AstraZeneca and Japan’s HOYA add a rising international tilt, quietly pulling their weight. On the flip side, Boston Scientific and Intuitive Surgical have been lagging, acting as a bit of a drag on this otherwise innovation-focused health care lineup.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 10.91% | $2.27M | $835.18B | -1.03% | 72 Outperform | |
| Johnson & Johnson | 8.43% | $1.76M | $547.64B | 45.05% | 78 Outperform | |
| AstraZeneca | 6.29% | $1.31M | $292.69B | 32.74% | 80 Outperform | |
| Merck & Company | 5.77% | $1.20M | $276.38B | 32.50% | 80 Outperform | |
| Boston Scientific | 4.91% | $1.02M | $92.25B | -41.33% | 79 Outperform | |
| Intuitive Surgical | 4.52% | $943.39K | $170.78B | -8.37% | 78 Outperform | |
| Thermo Fisher | 4.49% | $936.55K | $174.55B | 11.08% | 72 Outperform | |
| Argenx Se | 3.99% | $831.55K | $48.29B | 26.21% | 79 Outperform | |
| HOYA | 3.94% | $822.08K | ¥9.65T | 50.62% | 74 Outperform | |
| Guardant Health | 3.81% | $794.55K | $11.66B | 84.41% | 61 Neutral |
GDOC Technical Analysis
Negative
―
Price Trends
33.02
Negative
34.26
Negative
33.68
Negative
Market Momentum
-0.30
Positive
44.34
Neutral
12.78
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GDOC, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 32.79, equal to the 50-day MA of 33.02, and equal to the 200-day MA of 33.68, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 12.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDOC.
GDOC Peer Comparison
Comparison Results
Performance Comparison
GDOC
Goldman Sachs Future Health Care Equity ETF
32.13
0.92
2.95%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
LGHT
Langar Global HealthTech ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents